Locl Pharma, Inc.
USPTO PatentsView assignee record - 14 granted patents across 2 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Locl ranks #20,022 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 2 technology areas.
- #20,022
- of 49,997 US assignees by volume
- 30th percentile
- by Innovation Score (29.4/100)
- 34.6
- avg claims per patent
- -92%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R20022 · US Corporation #20,022 · 14 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 14 grants
- MID-PACK #20,022/49,997
- PHOTO-FINISH LIA Diagnostics
- CPC-NARROW A61P · 2 areas
- INNOV-THIN 29.4/100
- CLAIMS-DENSE 34.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -92% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: LIA Diagnostics, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Locl’s 29.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Locl
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Locl Pharma · this assignee 29
Locl Pharma · this assignee
29 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Locl's Innovation Score is 29.4/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Locl?
Each dot is one of Locl’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Locl’s own 34.6 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Locl's grants concentrate
Locl Pharma, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (9 grants) versus a trough of 1 in 2020. By volume, Locl sits between LIA Diagnostics, Inc. and Lontra Limited.
Who files at Locl's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- LIA Diagnostics
LIA Diagnostics, Inc.
14 patents
- Liebherr-elektron…
Liebherr-elektronik GMBH
14 patents
- Lindsey Manufactu…
Lindsey Manufacturing Co.
14 patents
- Livingstyle Enter…
Livingstyle Enterprises Limited
14 patents
- Locus OIL IP
Locus OIL IP Company, LLC
14 patents
- Logan Clutch
Logan Clutch Corporation
14 patents
- Logue AND PTY AS…
Logue AND Co. PTY Ltd., AS Trustee FOR A.T. & L.M. Logue Family Trust
14 patents
- Lontra
Lontra Limited
14 patents
- Locl Pharma ◀
Locl Pharma, Inc.
14 patents
What this shows Locl holds 14 patents at rank #20,005, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Locl
By rank, the assignees closest to #20,005 in granted patent volume.
- LIA Diagnostics, Inc. #20,001 · 14 patents
- Liebherr-elektronik GMBH #20,002 · 14 patents
- Lindsey Manufacturing Co. #20,003 · 14 patents
- Livingstyle Enterprises Limited #20,004 · 14 patents
- Locus OIL IP Company, LLC #20,006 · 14 patents
- Logan Clutch Corporation #20,007 · 14 patents
- Logue AND Co. PTY Ltd., AS Trustee FOR A.T. & L.M. Logue Family Trust #20,008 · 14 patents
- Lontra Limited #20,009 · 14 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Locl's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Locl's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 30th percentile higher than 30% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 9 | 64.3% |
| 2017 | 2 | 14.3% |
| 2018 | 2 | 14.3% |
| 2020 | 1 | 7.1% |
Which technologies does Locl Pharma, Inc. patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Locl Pharma, Inc.'s patent record in context - here's where to go next.
- Locl Pharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #20,022 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Locl Pharma, Inc. against LIA Diagnostics, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 29.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.